AIMS: We investigated the effects of the nuclear factor kappa B (NFkappaB) blocker pyrrolidine dithiocarbamate (PDTC) on high-fat diet (HFD)-induced metabolic and renal alterations in obese and lean Zucker rats (OZR and LZR, respectively). MAIN METHODS: Rats were fed a HFD resembling the typical "Western" diet or a regular diet (RD) and allowed free access to tap water or tap water containing PDTC (150 mg/kg body weight) for 10 weeks; rats were then sacrificed. Total ROS production rates were measured using electron paramagnetic resonance spectroscopy, and superoxide production was measured with lucigenin assay. Blood, plasma, and urine were analyzed. Semi-quantitative reverse transcriptase-polymerase chain reaction and electrophoretic mobility shift assay were conducted to assess NFkappaB mRNA levels and DNA binding activities, respectively; immunofluorescence was performed to assess protein levels. KEY FINDINGS: OZR-HFD rats exhibited significantly higher levels of total renal cortical reactive oxygen species production, plasma lipids, insulin, C-reactive protein, blood urea nitrogen, creatinine, and urinary albumin excretion than all other groups (p<0.05); these changes were accompanied by a significant decrease in plasma high density lipoprotein levels (p<0.05). Gene expression levels of desmin, cytokine and oxidative stress genes were significantly higher in the renal cortical tissues of OZR-HFD; NFkappaB p65 DNA binding activity was also significantly higher in these animals. PDTC attenuated these changes. SIGNIFICANCE: Our data suggest that NFkappaB blockade may prove beneficial in treating the nephropathy often associated with metabolic syndrome.
AIMS: We investigated the effects of the nuclear factor kappa B (NFkappaB) blocker pyrrolidine dithiocarbamate (PDTC) on high-fat diet (HFD)-induced metabolic and renal alterations in obese and lean Zucker rats (OZR and LZR, respectively). MAIN METHODS:Rats were fed a HFD resembling the typical "Western" diet or a regular diet (RD) and allowed free access to tapwater or tapwater containing PDTC (150 mg/kg body weight) for 10 weeks; rats were then sacrificed. Total ROS production rates were measured using electron paramagnetic resonance spectroscopy, and superoxide production was measured with lucigenin assay. Blood, plasma, and urine were analyzed. Semi-quantitative reverse transcriptase-polymerase chain reaction and electrophoretic mobility shift assay were conducted to assess NFkappaB mRNA levels and DNA binding activities, respectively; immunofluorescence was performed to assess protein levels. KEY FINDINGS: OZR-HFD rats exhibited significantly higher levels of total renal cortical reactive oxygen species production, plasma lipids, insulin, C-reactive protein, blood ureanitrogen, creatinine, and urinary albumin excretion than all other groups (p<0.05); these changes were accompanied by a significant decrease in plasma high density lipoprotein levels (p<0.05). Gene expression levels of desmin, cytokine and oxidative stress genes were significantly higher in the renal cortical tissues of OZR-HFD; NFkappaB p65 DNA binding activity was also significantly higher in these animals. PDTC attenuated these changes. SIGNIFICANCE: Our data suggest that NFkappaB blockade may prove beneficial in treating the nephropathy often associated with metabolic syndrome.
Authors: T Nishikawa; D Edelstein; X L Du; S Yamagishi; T Matsumura; Y Kaneda; M A Yorek; D Beebe; P J Oates; H P Hammes; I Giardino; M Brownlee Journal: Nature Date: 2000-04-13 Impact factor: 49.962
Authors: John F Keaney; Martin G Larson; Ramachandran S Vasan; Peter W F Wilson; Izabella Lipinska; Diane Corey; Joseph M Massaro; Patrice Sutherland; Joseph A Vita; Emelia J Benjamin Journal: Arterioscler Thromb Vasc Biol Date: 2003-01-30 Impact factor: 8.311
Authors: T M Coimbra; U Janssen; H J Gröne; T Ostendorf; U Kunter; H Schmidt; G Brabant; J Floege Journal: Kidney Int Date: 2000-01 Impact factor: 10.612
Authors: J H Bae; E Bassenge; K B Kim; Y N Kim; K S Kim; H J Lee; K C Moon; M S Lee; K Y Park; M Schwemmer Journal: Atherosclerosis Date: 2001-04 Impact factor: 5.162
Authors: T Inoguchi; P Li; F Umeda; H Y Yu; M Kakimoto; M Imamura; T Aoki; T Etoh; T Hashimoto; M Naruse; H Sano; H Utsumi; H Nawata Journal: Diabetes Date: 2000-11 Impact factor: 9.461
Authors: Deepmala Agarwal; Carrie M Elks; Scott D Reed; Nithya Mariappan; Dewan S A Majid; Joseph Francis Journal: Antioxid Redox Signal Date: 2011-09-22 Impact factor: 8.401
Authors: Nithya Mariappan; Carrie M Elks; Srinivas Sriramula; Anuradha Guggilam; Zhizhen Liu; Olga Borkhsenious; Joseph Francis Journal: Cardiovasc Res Date: 2009-09-03 Impact factor: 10.787
Authors: Carrie M Elks; Scott D Reed; Nithya Mariappan; Barbara Shukitt-Hale; James A Joseph; Donald K Ingram; Joseph Francis Journal: PLoS One Date: 2011-09-15 Impact factor: 3.240